Home/Biosimilar Atlas/Ranibizumab/Reliance Life Sciences ranibizumab

Reliance Life Sciences ranibizumab

Ranibizumab biosimilar developed by Reliance Life Sciences. Reference product Lucentis.

Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Reliance Life Sciences
FDAnot listed
EMAnot listed
CDSCOMar 2020permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Mar 2020
Application or permission
MF/BIO/20/000024; drug substance MF/BIO/20/000026; additional indications MF/BIO/24/000077
Indications as licensed
Wet AMD at permission; RVO, DME, diabetic retinopathy added July 2024
Presentations
2.3 mg/0.23 mL and 1.38 mg/0.23 mL vials
Source
S011
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All ranibizumab biosimilars

Planning ranibizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.